Peptides as NS3-serine protease inhibitors of hepatitis C virus

A compound, including enantiomers, stereoisomers, rotamers and tautomers of said compound, and pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formula I:

• wherein:
• G, J and Y may be the same or different and are independently selected from the group consisting of the moieties:
• H, alkyl, alkyl-aryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkyloxy, alkyl-aryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkyl-arylamino, arylamino, heteroarylamino, cycloalkylamino and heterocycloalkylamino, with the proviso that Y maybe additionally optionally substituted with X11 or X12;
• X11 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl, aryl, alkylaryl, arylalkyl, heteroaryl, alkylheteroaryl, or heteroarylalkyl moiety, with the proviso that X11 may be additionally optionally substituted with X12;
• X12 is hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, alkylsulfonamido, arylsulfonamido, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy, alkylureido, arylureido, halogen, cyano, or nitro, with the proviso that said alkyl, alkoxy, and aryl may be additionally optionally substituted with moieties independently selected from X12;
• R1 is COR5 wherein R5 is COR7 wherein R7 is NHR10, wherein R10 is selected from the group consisting of —CH(R1′)CONHCH(R2′)COO R11, CH(R1′)CONHCH(R2′)CONR12R13, CH(R1′)CONHCH(R2′)R′, CH(R1′)CONHCH(R2′)CONHCH(R3′)COOR11, CH(R1′)CONHCH(R2′)CONHCH(R3′)CONR12R13, CH(R1′)CONHCH(R2′)CONHCH(R3′)CONHCH(R4′)COOR11, CH(R1′)CONHCH(R2′)CONHCH(R3′)CONHCH(R4′)CONR12R13, CH(R1′)CONHCH(R2′)CONHCH(R3′)CONHCH(R4′)CONHCH(R5′)COOR11, and CH(R1′)CONHCH(R2′)CONHCH(R3′)CONHCH(R4′)CONHCH(R5′)CONR12R13, wherein R1′, R2′, R3′, R4′, R5′, R11, R12 and R13 may be the same or different and are independently selected from a group consisting of H, alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl-alkyl and heteroaralkyl;
• Z is selected from O, N, or CH;
• W maybe present or absent, and if W is present, W is selected from C═O, C═S, or SO2;
• and
• R′, R2, R3 and R4 are independently selected from the group consisting of H;
• C1-C10 alkyl;
• C2-C10 alkenyl;
• C3-C8 cycloalkyl;
• C3-C8 heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino other than for R2, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro;
• oxygen, nitrogen, sulfur, or phosphorus atoms (with said oxygen, nitrogen, sulfur, or phosphorus atoms numbering zero to six);
• (cycloalkyl)alkyl and (heterocycloalkyl)alkyl, wherein said cycloalkyl is made of three to eight carbon atoms, and zero to six oxygen, nitrogen, sulfur, or phosphorus atoms, and said alkyl is of one to six carbon atoms;
• aryl;
• heteroaryl;
• alkyl-aryl;
• and alkyl-heteroaryl;
• wherein said alkyl, heteroalkyl, alkenyl, heteroalkenyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties may be optionally substituted, with said term “substituted” referring to optional and chemically-suitable substitution with one or more moieties selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, heterocyclic, halogen, hydroxy, thio, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, sulfonamide, sulfoxide, sulfone, sulfonylurea, hydrazide, and hydroxamate;
• with the proviso that R2 is not arylalkyl or cyclohexylalkyl.